Several groups have mapped a herpes simplex virus (HSV) neurovirulence locus to the long repeat sequence between the 'a' sequence and 5' end of the IE1 gene (Thompson et al., 1983 (Thompson et al., , 1989 Taha et al., 1988a, b; Chou et al., 1990; MacLean et al., 1991) . However, there has been controversy over the protein-coding potential of this region. In 1986 Ackermann et al., using an antiserum against a peptide consisting of the trimer proline-alanine-threonine repeated 10 times [(PAT)a0] from a predicted open reading frame (ORF) of HSV-I(F), identified a 43K polypeptide, named ICP34.5, whose sequence was subsequently revised (Chou & Roizman, 1990) . This polypeptide has subsequently been shown to play a crucial role in HSV-I(F) neurovirulence (Chou et al., 1990) . However, at the time there was no identified equivalent ORF in HSV-I(17) . Subsequently the published sequence for this HSV-I(17) region has also been amended and shown to encode an ORF, designated RL 1, equivalent to the ICP34.5 of HSV-1 (F) Dolan et al., 1992) . The number of copies of the PAT repeat varies between strains, being present 10 times in HSV-I(F) giving an ICP34.5 of 263 amino acids in length but only five times in HSV-I(17) giving an ICP34.5 of 248 amino acids.
Our aim was to examine directly whether the HSV-1(17) ORF, RL1, encodes a polypeptide equivalent to HSV-I(F) ICP34.5. As a control the non-neurovirulent HSV-I(17) deletion variant 1716, which has a mutation in RL1, was used. Antisera were raised against seven different peptides from RL1 (Table 1 and Fig. 1 ). These antisera were screened by Western blot and immunoprecipitation against both HSV-I(F)-and HSV-l(17)-infected cells extracts. Only two of the peptide antisera recognized an HSV-specific polypeptide (3 and 4, Table 1 and Fig. 1 ). On Western blots antisera to peptide 3, a branched peptide containing seven repeats of the PAT trimer, reacted weakly at a 1 : 10 dilution with a 39K HSV-I(F) polypeptide but failed to recognize an HSV-1 (17) protein specifically (data not shown).
In contrast, sera raised against a linear peptide containing 10 repeats of the PAT trimer (peptide 4) coupled to a carrier protein, keyhole limpet haemocyanin, reacted strongly (down to a 1 : 1000 dilution) with a 39K HSV-I(F) polypeptide and weakly with a 37K HSV-I(17) polypeptide (Fig. 2a) . This interaction was specific: the protein was not detected in extracts from either mock-infected cells or cells infected with the HSV-1(17) RL1 deletion variant 1716 (Fig. 2a) ; no reaction was detected using preimmune sera (data not shown); interactions were completely blocked by the addition of 0001-1724 © 1993 SGM 1991) and an African swine fever virus gene (Sussman et al., 1992) . The position of the peptides against which antisera were raised are marked above the line. The sequence and form of the peptides are given in more detail in Table 1. either peptide 4 or peptide 3 but not by an unrelated peptide ( Fig. 2b ). In the HSV-I(F) extract used there were multiple ICP34.5-related bands (M r 28K to 39K) recognized specifically by antiserum 4. These were not consistently found in different extracts made from the same HSV-I(F) virus stock and are thus unlikely to represent heterogeneity in the HSV-I(F) stock. The relationship between these bands is at present unknown, but interestingly the smallest corresponds to the expected M r of a 263 amino acid polypeptide. As far as we know these have not been previously observed (Ackermann et al., 1986) . In antigen titration experiments, the HSV-I(F) protein was detectable down to a 1 : 256 dilution of the infected cell extract, whereas the HSV-I(17) protein could only be detected down to a 1 : 8 dilution (data not shown). This difference in detection level (approximately 32-fold) could reflect either lower levels of ICP34.5 in HSV-l(17)-infected cells (there is no obvious difference in levels of other infected cell proteins such as Vmw21) or lower antibody affinity for the HSV-I(17) polypeptide. The HSV-I(17) ICP34.5 contains five copies of the PAT repeat compared to the 10 copies in the HSV-I(F) polypeptide. This might reduce the affinity of the antiserum for the HSV-I(17) polypeptide. The significantly weaker reactivity of the anti-(PAT)7 sera compared to the anti-(PAT)l 0 sera would support the latter possibility. To determine whether there are different levels of ICP34.5 present in HSV-I(17)-and HSV-I(F)-infected cells, an antiserum against an epitope that is completely conserved between HSV-1 (17) and HSV-1 (F) would be required; to date all such antisera have failed to recognize ICP34.5 ( Fig. 1 and Table 1 ). Interestingly, Ackermann et al. (1986) , using a serum raised against an identical peptide, (PAT)I 0, failed to detect ICP34.5 in either HSV-1 strains HFEM or MP. We have failed to detect ICP34.5 in HSV-1 strains HFEM, KOS and MP. The apparent M r of the HSV-I(F) polypeptide is 39K compared with 43K demonstrated by Ackermann et al. (1986) due to our use of different gel systems (Marsden et al., 1976 (Marsden et al., , 1978 . Immunoprecipitation reactions were also carried out. The anti-(PAT)l o serum precipitated a 39K HSV-I(F) polypeptide from extracts labelled with either [35S]cysteine or [a2P]orthophosphate. The specifity of this reaction was again confirmed by peptide inhibition (data not shown). In immunoprecipitation reactions no HSV-1(17) polypeptide was detected by the anti-(PAT)l 0 sera (data not shown).
The accumulation of ICP34.5 at various times postinfection (p.i.) was studied. BHK21 C13 cells were infected at an m.o.i, of 20 p.f.u./cell with either HSV-1(17) or HSV-I(F), and samples were harvested every 2 h from 0 to 12 h and thereafter every 4 h up to 24 h p.i. presence of phosphonoacetic acid (PAA; an inhibitor of HSV DNA synthesis) were also harvested at 24 h p.i. Samples were analysed by Western blotting. Similar kinetics of accumulation were observed with both HSV-I(F) and HSV-l(17); synthesis was first detected 2 h p.i. and polypeptide levels gradually increased until they reached a plateau by 8 h p.i. At 24 h p.i. the level of ICP34.5 was approximately twofold lower in the presence of PAA than in its absence (Fig. 3) . The absence ofVmw21 (a true late polypeptide) (Johnson et al., 1986) confirmed that the PAA blocked HSV DNA synthesis (data not shown). ICP34.5 shows similar kinetics of accumulation to those of gD (Johnson et al., 1986) and can thus be designated a delayed early polypeptide in agreement with the classification of the HSV-I(F) ICP34.5 promoter as Yl by Chou & Roizman (1986) . From the data presented in this paper we have demonstrated that the HSV-l(17) R L 1 0 R F , located between the 'a' sequence and 5' end of the IE1 gene (Dolan et al., 1992) , encodes a polypeptide equivalent to the ICP34.5 of HSV-I(F). The predicted amino acid sequences of the two polypeptides are very similar. Not surprisingly therefore, both proteins showed similar kinetics of accumulation and were localized almost exclusively in the cytoplasm [a low level detected in the nucleus (< 1/320) was probably due to cytoplasmic contamination] and were not associated with membranes (Fig. 4) . This cytoplasmic localization was also reported by A c k e r m a n n et al. (1986) . In addition I C P 3 4 . 5 was not detectable in virions (Fig. 4) . H S V -I ( F ) I C P 3 4 . 5 is phosphorylated, and it is also likely that HSV-I(17) I C P 3 4 . 5 will be a phosphoprotein. As expected, the n o nneurovirulent HSV-I(17) variant 1716 (with a deletion removing 9 0 % of the R L 1 0 R F ) fails to synthesize I C P 3 4 . 5 . This demonstrates that, as is the case with H S V -I ( F ) (Chou et al., 1990 ), I C P 3 4 . 5 of HSV-I(17) plays a crucial role in HSV replication in the nervous system ( M a c L e a n et al., 1991).
Cells infected with HSV-I(17) or HSV-I(F) in the
The two m a i n differences between the H S V -I ( F ) a n d HSV-I(17) polypeptides are in their apparent MrS and the level of their detection. The slight decrease in electrophoretic mobility of the H S V -I ( F ) polypeptide (apparent M r 39K compared to 37K) is p r o b a b l y due to the presence of 15 extra a m i n o acids. The difference in the level of detection of the H S V -I ( F ) a n d HSV-I(17) polypeptides m a y be due either to weaker a n t i b o d y affinity for the HSV-I(17) polypeptide or to a lower level of a c c u m u l a t i o n of the HSV-I(17) polypeptide. Additional antisera will be required to address this question; we are currently attempting to express the HSV-I(17) polypeptide in Escherichia coli to generate an antiserum against the whole protein. It has been shown previously that the level of a c c u m u l a t i o n of HSV polypeptides m a y vary considerably between strains (Marsden et al., 1976 (Marsden et al., , 1978 ( Received 25 Mareh 1993; Accepted 22 June 1993) 
